4-ethoxymethoxypyridine | 120017-23-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-ethoxymethoxypyridine
• 英文别名: 4-(Ethoxymethoxy)pyridine
• CAS: 120017-23-4
• 化学式: C₈H₁₁NO₂
• 分子量: 153.181
• InChiKey: DHALEYBIFWDUCN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  31.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-羟基吡啶 、 氯甲基乙醚 以8%的产率得到
  参考文献：
  名称：

  PERVEZ, HUMAYUN;ONYIRIUKA, SAMUEL O.;REES, LILIAS;ROONEY, JAMES R.;SUCKLI+, TETRAHEDRON, 44,(1988) N 14, C. 4555-4568

  摘要：

  DOI：

文献信息

• [EN] COMPOUNDS FOR AND METHODS OF TREATING DISEASES<br/>[FR] COMPOSÉS ET MÉTHODES DE TRAITEMENT DE MALADIES
  申请人：ALTERITY THERAPEUTICS LTD

  公开号：WO2020186291A1

  公开（公告）日：2020-09-24

  The present invention provides compounds that modulate biological metals and to pharmaceutical compositions containing such compounds. The invention particularly relates to imidazo[1,5-a]pyridine compounds that modulate iron and are useful for the treatment of diseases, particularly neurological diseases such as Parkinson's disease (PD), Alzheimer's 5 disease (AD), Alzheimer-type dementia, Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and multiple system atrophy (MSA).

  本发明提供了调节生物金属的化合物，并含有这些化合物的药物组合物。该发明特别涉及调节铁的咪唑[1,5-a]吡啶化合物，用于治疗疾病，特别是神经系统疾病，如帕金森病（PD）、阿尔茨海默病（AD）、阿尔茨海默型痴呆、亨廷顿病（HD）、肌萎缩侧索硬化症（ALS）、额颞叶痴呆（FTD）和多系统萎缩（MSA）。
• Selective functionalisatlon
  作者：Humayun Pervez、Samuel O. Onyiriuka、Lilias Rees、James R. Rooney、Colin J. Suckling

  DOI：10.1016/s0040-4020(01)86158-5

  日期：1988.1

  tetrafluoroborate or nitrogen dioxide to yield activated intermediates capable of selectively nitrating phenol ortho to the hydroxyl group with virtually complete selectivity and in quantitative yield in aprotic solvents. Although the nitration of phenol itself is exceptionally selective, the nitration of some substituted phenols lead to mixtures of mononitrated products and in especially reactive cases such

  已显示带有羧酸盐侧链和吡啶酮的吡啶鎓盐与四氟硼酸硝鎓或二氧化氮反应生成活化的中间体，该中间体能够在非质子溶剂中以几乎完全的选择性和定量收率选择性地硝化邻苯二酚成羟基。尽管苯酚的硝化作用本身具有极高的选择性，但某些取代的苯酚的硝化作用会导致单硝化产物的混合物，特别是在反应性情况下，例如4-甲氧基苯酚和萘酚，也会生成二硝化产物。反应可以最方便地在聚合物载体上进行。光谱证据表明，吡啶鎓盐和酚之间的分子间缔合是在类似于反应条件的条件下发生的，并且酚羟基和吡啶环上的受体基团之间也可以发生氢键键合。建议将这两种作用结合起来可观察到选择性。概述了将反应范围扩大到其他亲电子试剂和底物的尝试。
• Imidazo [1,5-a]pyridine compounds and their use
  申请人：Alterity Therapeutics Limited

  公开号：US10941143B2

  公开（公告）日：2021-03-09

  The present invention provides compounds that modulate biological metals and to pharmaceutical compositions containing such compounds. The invention particularly relates to imidazo[1,5-a]pyridine compounds of formula (I) that modulate iron and are useful for the treatment of diseases, particularly neurological diseases such as Parkinson's disease (PD), Alzheimer's disease (AD), Alzheimer-type dementia, Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and multiple system atrophy (MSA). The compounds of formula (I) being where variables are defined herein.

  本发明提供了调节生物金属的化合物以及含有此类化合物的药物组合物。本发明尤其涉及式（I）的咪唑并[1,5-a]吡啶化合物，该化合物可调节铁元素并可用于治疗疾病，尤其是神经系统疾病，如帕金森病（PD）、阿尔茨海默病（AD）、阿尔茨海默型痴呆、亨廷顿病（HD）、肌萎缩性脊髓侧索硬化症（ALS）、额颞叶痴呆（FTD）和多系统萎缩（MSA）。式(I)化合物为 其中变量的定义见本文。
• COMPOUNDS FOR AND METHODS OF TREATING DISEASES
  申请人：Alterity Therapeutics Limited

  公开号：US20200291021A1

  公开（公告）日：2020-09-17

  The present invention provides compounds that modulate biological metals and to pharmaceutical compositions containing such compounds. The invention particularly relates to imidazo[1,5-a]pyridine compounds that modulate iron and are useful for the treatment of diseases, particularly neurological diseases such as Parkinson's disease (PD), Alzheimer's disease (AD), Alzheimer-type dementia, Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and multiple system atrophy (MSA).